Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom

Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom: a Randomised Placebo-controlled Study

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080222009

Enrollment

Registered

2013-01-24

Start date

2013-01-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD) and Asthma

Interventions

investigational material(s) Generic name etc : Lysozyme hydrochloride (LYS) INN of investigational material : Therapeutic category code : 395 Enzyme preparations Dosage and Administration for Investi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: For COPD: Diagnosis of COPD Forced expiratory volume in 1 second (FEV1) of <80% of the predicted value Ratio of FEV1 to forced vital capacity (FVC) of <70% Symptom of expectorated sputum Brinkman index 200 or more Smoking history For Asthma: Diagnosed partly controlled by global initiative for asthma Symptom of expectorated sputum Scored between 20 to 24 by ACT (Asthma Control Test)

Exclusion criteria

Exclusion criteria: Patients with egg allergy Patients with domiciliary oxygen therapy Patients with pneumonia or pulmonary tuberculosis Patients with severe cardiovascular disorder, severe kidney disorder, severe hepatic disorder, severe hematological disorder Patients with cancer

Design outcomes

Primary

Measure	Time frame
Efficacy Peripheral airway resistance and reactance measured by Impulse oscillometry system, and NO concentration Change of several inflammatory or biochemical marker concentration in inducted sputum	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026